Kenneth I. Moch, of Cognition Therapeutics, Inc., has broad expertise building, managing and financing private and public life science companies from start-up through commercialization, and has helped build five companies which have pioneered novel technologies. Ken is currently President & CEO of Cognition Therapeutics, Inc., developing novel treatments for Alzheimer’s disease, and has served as President & CEO of other life science companies including Chimerix, Inc., Alteon, Inc. (Nasdaq:ALTN), and Biocyte Corporation. Earlier in his career, he was a co-founder and served as Vice President of The Liposome Company, Inc. (Nasdaq:LIPO), and as Managing Director of Healthcare Investment Banking at ThinkEquity Partners as well as management consultant with McKinsey & Company.
Ken has deep insights into the full spectrum of the strategic and tactical complexities and issues facing life science companies. Through his experiences, Ken has been responsible for the successful completion of more than 30 public offerings and private placements, many under difficult market and/or product development conditions, and has negotiated corporate partnering deals with numerous large pharmaceutical companies. In addition, Ken has a deep knowledge of the complexities of the regulatory process, and has been actively involved in assembling multidisciplinary teams and working with key opinion leaders to design and implement clinical trial strategies and deal with regulatory issues.
Building on his longstanding interest in health policy, Ken served for over a decade on the Board of the Biotechnology Industry Organization (BIO), as Secretary of BIO’s Emerging Companies Section, and as a member of the BIO’s BioEthics Committee. He is a member of the Board of North Carolina Bio (NCBio), and is a past Chairman of Bio New Jersey (BioNJ) and a past member of the Executive Committee of the New York Biotechnology Association. Ken is a member of the NYU Working Group on Compassionate Use and Pre-Approval Access and, in August 2014, Ken and Arthur Caplan, the Head of Medical Ethics at NYU Medical Center, co-authored an article in Health Affairs on the ethical issues surrounding access to experimental medicines, “Rescue Me: The Challenge Of Compassionate Use In The Social Media Era.” In March 2015 Ken contributed an Op-Ed to The Wall Street Journal entitled, “Wanted: Guidelines for Access to Experimental Drugs.” Ken currently serves on the Board of Zynerba, Inc. (Nasdaq:ZYNE), and as a member of the Board of M2Gen – Moffitt Genetics Corporation, the personalized medicine subsidiary of Moffitt Cancer Center. He holds an A.B. in biochemistry from Princeton University and an MBA from the Stanford University Graduate School of Business.